Verona Pharma plc
Verona Pharma plc (VRNA): 11 pipeline candidates · ~16 mo cash runway · 25 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.7 months
D/E 1.06 · 6% dilution
Lead: Phase 3
11 candidates
N/A
N/A
A transparent, data-derived signal for Verona Pharma plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$438.0M
Quarterly Burn
$89.8M
Runway
15.7 mo
Revenue
$103.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| Ensifentrine (nebulized) - asthma | Phase 3 |
| Ensifentrine (nebulized) - bronchiectasis | Phase 3 |
| Ensifentrine (nebulized) - cystic fibrosis | Phase 3 |
| Ensifentrine / glycopyrrolate fixed-dose combination | Phase 3 |
| Ensifentrine 1.5 mg | Phase 2 |
| Ensifentrine 3 mg | Phase 2 |
| Ensifentrine 3 mg twice daily | Phase 3 |
| Glycopyrrolate | Phase 2 |
| Glycopyrrolate 21.25 mcg | Phase 2 |
| Glycopyrrolate 42.5 mcg | Phase 2 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Verona Pharma plc's pipeline?
Verona Pharma plc (VRNA) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Verona Pharma plc's lead drug candidate?
Verona Pharma plc's most advanced tracked candidate is Ensifentrine (nebulized) - asthma (Phase 3) for Chronic Obstructive Pulmonary Disease; COPD.
What is Verona Pharma plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Verona Pharma plc has approximately 15.7 months of cash runway.
Who is the CEO of Verona Pharma plc?
Chief Executive Officer is the chief executive officer of Verona Pharma plc (VRNA).
Get the full picture on Verona Pharma plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.